Vaxcyte/PCVX
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX
About Vaxcyte
Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-24, VAX-A1, and VAX-PG.
Ticker
PCVX
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
San Carlos, United States
Employees
254
Website
vaxcyte.com
Vaxcyte Metrics
BasicAdvanced
$8.3B
Market cap
-
P/E ratio
-$4.22
EPS
0.94
Beta
-
Dividend rate
Price and volume
Market cap
$8.3B
Beta
0.94
Financial strength
Current ratio
17.417
Quick ratio
17.16
Long term debt to equity
1.019
Total debt to equity
1.382
Management effectiveness
Return on assets (TTM)
-20.62%
Return on equity (TTM)
-29.83%
Valuation
Price to book
4.16
Price to tangible book (TTM)
4.16
Price to free cash flow (TTM)
-16.32
Growth
Earnings per share change (TTM)
24.09%
3-year earnings per share growth
27.92%
What the Analysts think about Vaxcyte
Analyst Ratings
Majority rating from 9 analysts.
Vaxcyte Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$95M
-47.46%
Profit margin
0.00%
NaN%
Vaxcyte Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.70
-$0.91
-$1.82
-$0.85
-
Expected
-$0.75
-$0.84
-$1.07
-$1.17
-$0.99
Surprise
-6.04%
8.66%
69.78%
-27.27%
-
Vaxcyte News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Vaxcyte stock?
Vaxcyte (PCVX) has a market cap of $8.3B as of July 04, 2024.
What is the P/E ratio for Vaxcyte stock?
The price to earnings (P/E) ratio for Vaxcyte (PCVX) stock is 0 as of July 04, 2024.
Does Vaxcyte stock pay dividends?
No, Vaxcyte (PCVX) stock does not pay dividends to its shareholders as of July 04, 2024.
When is the next Vaxcyte dividend payment date?
Vaxcyte (PCVX) stock does not pay dividends to its shareholders.
What is the beta indicator for Vaxcyte?
Vaxcyte (PCVX) has a beta rating of 0.94. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Vaxcyte stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.